114027
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
成人发热感染相关癫痫综合征（FIRES）的生酮饮食疗法：五例患者病例系列及临床疗效分析
Authors Fan M, Li Y, Diao H, Wang Y
Received 21 October 2025
Accepted for publication 17 December 2025
Published 24 December 2025 Volume 2025:18 Pages 6875—6888
DOI https://doi.org/10.2147/IDR.S574683
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Oliver Planz
Minghua Fan,* Yan Li,* Haiyan Diao, Yanhong Wang
Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanhong Wang, Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China, Email wangyanhong2627@sxbqeh.com.cn
Objective: This study reports five clinical cases of adult Febrile Infection-Related Epilepsy Syndrome (FIRES) treated with a ketogenic diet (KD). The aim is to explore the clinical efficacy, safety, optimal initiation timing, and related efficacy factors of KD in adult FIRES through case analysis, and to provide reference for clinical decision-making.
Methods: We retrospectively reviewed the medical records of five FIRES patients treated with KD at Shanxi Bethune Hospital between October 2019 and January 2025.
Results: Among the five FIRES patients (2 males, 3 females), with a median age of 32 years [interquartile range (IQR) 25– 34]. All patients presented with refractory status epilepticus following a febrile illness. EEG revealed slowed background activity with multifocal epileptiform discharges, and 60% (3/5) showed abnormal brain MRI findings. All patients received multidrug antiseizure therapy, anesthetics, and immunotherapy. KD was initiated at a median of 33 days (IQR 10– 50) post-onset. Ketosis was achieved within a median of 2 days (IQR 2– 3), followed by significant seizure reduction after a median of 3 days (IQR 3– 4) of KD. At discharge, mRS scores were 2 (40%) or 4 (60%); by 3-month follow-up, all patients achieved an mRS score of 2. Common adverse effects included diarrhea (60%), hypoalbuminemia (100%), anemia (80%), fecal occult blood (60%), and hyperlipidemia (40%), all of which resolved with symptomatic management.
Conclusion: FIRES is a rare and devastating clinical syndrome with an unclear pathogenesis, high mortality, and poor prognosis, often accompanied by cognitive decline or severe neurological sequelae. KD appears effective in FIRES management; however, due to limited case data, further large-sample, prospective, or randomized controlled studies are needed to elucidate its short- and long-term efficacy in adult FIRES patients.
Keywords: febrile infection-related epilepsy syndrome, FIRES, ketogenic diet, new-onset refractory status epilepticus, NORSE, clinical efficacy, adverse effects
Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanhong Wang, Department of Neurology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, People’s Republic of China, Email wangyanhong2627@sxbqeh.com.cn
Objective: This study reports five clinical cases of adult Febrile Infection-Related Epilepsy Syndrome (FIRES) treated with a ketogenic diet (KD). The aim is to explore the clinical efficacy, safety, optimal initiation timing, and related efficacy factors of KD in adult FIRES through case analysis, and to provide reference for clinical decision-making.
Methods: We retrospectively reviewed the medical records of five FIRES patients treated with KD at Shanxi Bethune Hospital between October 2019 and January 2025.
Results: Among the five FIRES patients (2 males, 3 females), with a median age of 32 years [interquartile range (IQR) 25– 34]. All patients presented with refractory status epilepticus following a febrile illness. EEG revealed slowed background activity with multifocal epileptiform discharges, and 60% (3/5) showed abnormal brain MRI findings. All patients received multidrug antiseizure therapy, anesthetics, and immunotherapy. KD was initiated at a median of 33 days (IQR 10– 50) post-onset. Ketosis was achieved within a median of 2 days (IQR 2– 3), followed by significant seizure reduction after a median of 3 days (IQR 3– 4) of KD. At discharge, mRS scores were 2 (40%) or 4 (60%); by 3-month follow-up, all patients achieved an mRS score of 2. Common adverse effects included diarrhea (60%), hypoalbuminemia (100%), anemia (80%), fecal occult blood (60%), and hyperlipidemia (40%), all of which resolved with symptomatic management.
Conclusion: FIRES is a rare and devastating clinical syndrome with an unclear pathogenesis, high mortality, and poor prognosis, often accompanied by cognitive decline or severe neurological sequelae. KD appears effective in FIRES management; however, due to limited case data, further large-sample, prospective, or randomized controlled studies are needed to elucidate its short- and long-term efficacy in adult FIRES patients.
Keywords: febrile infection-related epilepsy syndrome, FIRES, ketogenic diet, new-onset refractory status epilepticus, NORSE, clinical efficacy, adverse effects